- Home
- YGMZ vs GTBP Comparison
YGMZ vs GTBP Comparison
Compare YGMZ & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YGMZ
- GTBP
- Stock Information
- Founded
- YGMZ 2002
- GTBP 1965
- Country
- YGMZ China
- GTBP United States
- Employees
- YGMZ N/A
- GTBP N/A
- Industry
- YGMZ Transportation Services
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- YGMZ Consumer Discretionary
- GTBP Health Care
- Exchange
- YGMZ Nasdaq
- GTBP Nasdaq
- Market Cap
- YGMZ 6.0M
- GTBP 6.6M
- IPO Year
- YGMZ 2020
- GTBP N/A
- Fundamental
- Price
- YGMZ $1.11
- GTBP $2.91
- Analyst Decision
- YGMZ
- GTBP
- Analyst Count
- YGMZ 0
- GTBP 0
- Target Price
- YGMZ N/A
- GTBP N/A
- AVG Volume (30 Days)
- YGMZ 38.4K
- GTBP 28.9K
- Earning Date
- YGMZ 01-01-0001
- GTBP 11-14-2024
- Dividend Yield
- YGMZ N/A
- GTBP N/A
- EPS Growth
- YGMZ N/A
- GTBP N/A
- EPS
- YGMZ N/A
- GTBP N/A
- Revenue
- YGMZ $89,002,243.00
- GTBP N/A
- Revenue This Year
- YGMZ N/A
- GTBP N/A
- Revenue Next Year
- YGMZ N/A
- GTBP N/A
- P/E Ratio
- YGMZ $13.88
- GTBP N/A
- Revenue Growth
- YGMZ N/A
- GTBP N/A
- 52 Week Low
- YGMZ $0.91
- GTBP $1.92
- 52 Week High
- YGMZ $6.24
- GTBP $10.66
- Technical
- Relative Strength Index (RSI)
- YGMZ 37.86
- GTBP 55.53
- Support Level
- YGMZ $1.14
- GTBP $2.94
- Resistance Level
- YGMZ $1.32
- GTBP $3.54
- Average True Range (ATR)
- YGMZ 0.08
- GTBP 0.27
- MACD
- YGMZ -0.03
- GTBP -0.02
- Stochastic Oscillator
- YGMZ 2.50
- GTBP 23.05
About YGMZ MingZhu Logistics Holdings Limited
MingZhu Logistics Holdings Ltd is a Holding company. Its business activities include trucking services and car owner services. Its segments are the trucking business, car owner services business, and liquor distribution business. It generates the majority of its revenue from the trucking segment.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.